Skip to main content
KLRS
NASDAQ Life Sciences

Kalaris Therapeutics Reports Strong Q1 Financials, Maintains Cash Runway into Q4 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$4.82
Mkt Cap
$99.158M
52W Low
$2.14
52W High
$11.88
52W Position info
125% above low
Off High info
59% below high
Rel. Volume info
2.0× avg
Market data snapshot near publication time

KLRS has more than doubled off its 52-week low of $2.14 on elevated volume (2.0× avg).

Summary

Kalaris Therapeutics announced its first quarter 2026 financial results, reporting $104.9 million in cash and maintaining its operational runway into Q4 2027, alongside progress in its Phase 1b/2 clinical study for TH103.


Key Events · Earnings and Guidance · KLRS

  • Strong Cash Position

    Kalaris reported $104.9 million in cash, cash equivalents, and marketable securities as of March 31, 2026.

  • Maintained Cash Runway

    The company reiterated its expectation that current cash will fund operations into the fourth quarter of 2027, providing a stable financial outlook.

  • Clinical Progress for TH103

    Patient screening is underway for the Phase 1b/2 study of TH103, with preliminary data anticipated in the first half of 2027, and Phase 3 trials on track for late 2027.

  • Post-ATM Financial Update

    This filing confirms the company's financial health after the recent activation of its $100 million At-The-Market offering, demonstrating successful capital infusion.


Analysis · KLRS · Life Sciences

This earnings report provides a crucial update following the recent activation of a $100 million At-The-Market (ATM) offering. The company's ability to maintain its cash runway guidance into Q4 2027, despite a quarterly burn, confirms the success of its capital raising efforts and provides financial stability for ongoing clinical development. The cash position exceeding the current market capitalization is a strong indicator of financial health for a clinical-stage biotech.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KLRS was trading at $4.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $99.2M. The 52-week trading range was $2.14 to $11.88. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KLRS - Latest Insights

KLRS
Nov 10, 2026, 4:00 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.85
Real-time Price: $1.43 info
Change: -$0.420 (-23%) info
Market Cap: $31.232M info
KLRS
Nov 10, 2026, 7:30 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.30
Real-time Price: $1.43 info
Change: -$0.8742 (-38%) info
Market Cap: $31.232M info
KLRS
Aug 11, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.27
Real-time Price: $1.43 info
Change: -$2.84 (-67%) info
Market Cap: $31.232M info
KLRS
Jul 17, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.66
Real-time Price: $1.43 info
Change: -$3.23 (-69%) info
Market Cap: $31.232M info
KLRS
Jul 17, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.58
Real-time Price: $1.43 info
Change: -$3.15 (-69%) info
Market Cap: $31.232M info